In addition to half-life evaluation, FcRn has great potential as a therapeutic target. The high affinity of FcRn has harmful effects on IgG-mediated autoimmune diseases such as myasthenia gravis, rheumatoid arthritis, or pemphigus vulgaris. Targeting FcRn and inhibiting FcRn circulation can enhance IgG catabolism, resulting in overall reduced IgG and pathogenic autoantibody levels, which is expected to reduce all autoimmune abnormalities caused by IgG. Studies have confirmed that FcRn targeting therapy provides faster and more selective IgG reduction than therapeutic plasma exchange therapy for myasthenia gravis. In addition, the advantages of this treatment over many clinically use conventional therapies are also demonstrated by the fact that IgA, IgD, IgE, and IgM are not dependent on FcRn-mediated circulation. Therefore, it does not lead to extensive immunosuppression, providing the basis for the safety and precision specificity of FcRn targeting.
Therefore, drugs that target FcRn do not use FcRn as a direct target for therapeutic intervention as conventional targets. Instead, it uses the advantages of cellular drug delivery, which is called a "revolutionary therapy" that can wipe out all autoimmune diseases, with high potential.
To support monoclonal antibody, bispecific antibody, ADC drug affinity research and targeted FcRn drug development for the treatment of autoimmune diseases, ACROBiosystems is providing you with a series of high-quality FcRn proteins.
Expressed by HEK293 Cells: to realize post-translational glycosylation and other modifications and correct protein folding
Various species: Human, Mouse, Cynomolgus/Rhesus macaque, Rat, Porcine, Rabbit, Feline, Bovine, can be fully applied to different cross species experiments
more than 95% as verified by SDS-PAGE
more than 90% as verified by SEC-MALS
Low endotoxin:＜1.0 EU/µg
Biotinylated FcRn proteins labeled with AvitagTM offered. The labeling efficiency is high, and the labeling site is specific and clear, which is suitable for ELISA/SPR/BLI detection based on binding to streptavidin in the process of drug development and process optimization
Affinity verified by SPR & BLI: high-bioactivity guaranteed, and protocols offered free of charge
|Molecule||Cat. No.||Host||Product Description||Structure|
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. The Journal of Clinical Inveatigation. 1972, 51:2916–27.
FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology. 2007,7:715–725.
FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. Journal of Controlled Release. 2021, 337 :248–257.
Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. Frontiers in Immunology. 2020, 10.